Annovis Bio Inc (ANVS)

$ANVS So that’s what that spike was. That’s a lot of money to throw down, yeyas! he BELIEVES! All you now put your hands togetha for the brutha. Yeyas indeed it’s amazin!

$ANVS What a brave move from Mr.Hoffman.He must know some thing .That the drug does works ,and there is news coming .Be very interesting what the news will be .

$ANVS Holy Moses. Brother went all in on open market buying. Bullish as a mothaf'er!

$ANVS $ANVS Amid noise, volatility, and mixed sentiment, it’s worth refocusing on fundamentals. Annovis Bio is advancing buntanetap, targeting neurotoxic proteins like beta-amyloid and tau, with potential in Alzheimer’s and Parkinson’s. Recent developments, including patent protection through 2044, reinforce the long-term thesis. At the same time, the market remains uncertain: • The stock is down significantly YTD • Price action is weak • Volume spikes suggest positioning, not confirmation This is where conviction meets discipline. I hold a position and I’m watching execution — partnerships, clinical progress, and communication. The opportunity is there, but so is the risk. In biotech, fundamentals take time… but when they materialize, they move fast. Curious to hear other perspectives.

$ANVS 715k volume candle wow

$ANVS https://www.annovisbio.com/press-release/annovis-secures-u-s-patent-for-buntanetap-in-the-prevention-and-treatment-of-neurological-injuries-caused-by-brain-infections

$ANVS https://www.annovisbio.com/press-release/annovis-secures-u-s-patent-for-buntanetap-in-the-prevention-and-treatment-of-neurological-injuries-caused-by-brain-infections

$ANVS Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections

$ANVS Amid all the noise and sentiment swings, it’s worth bringing the focus back to fundamentals. Annovis Bio is not a typical speculative biotech — its core value lies in its approach to neurodegenerative diseases, targeting multiple protein pathways rather than a single mechanism. The key variables to watch now are: • Clinical data consistency across indications (Alzheimer’s / Parkinson’s) • Regulatory pathway clarity • Cash runway and potential dilution risk • Strategic partnerships or licensing opportunities Price action at this stage is largely driven by sentiment and liquidity, not intrinsic value. Volatility is expected, especially in small-cap biotech. Personally, I hold a position and I’m less focused on short-term moves and more on whether the company can deliver credible data and secure partnerships that validate the platform. If execution follows, sentiment will change. If not, the market is already signaling skepticism.

$ANVS CEO, Dr. Maccecchini, has a nice smile in the photo at the New York Stock Exchange. This quote really is quite appropriate for those who trust Dr. Maccecchini and for those who don't believe what I have witnessed first hand: "Growing up is understanding that not everyone who smiles at you wishes you well, and not everyone who tells you the truth wishes you harm." https://www.youtube.com/shorts/t0QbXPFIw8E

$ANVS Another day and this POS is red again, will give back all yesterday's gain and more. This is headed to lower than $50MIL market cap and will force nasdaq delisting once again.

$ANVS Not raising additional funds end 2025 was a huge miss.

$ANVS https://www.the-scientist.com/buntanetap-from-execution-poison-to-potential-alzheimer-s-disease-drug-74274

$ANVS I don't like a promotional post for some other company having the top spot here, so I'll post my favorite ANVS graph, which shows dose-dependent cognitive improvement in early Alzheimer's patients treated for 3 months:

Jupiter Neurosciences, Inc. (NASDAQ: JUNS), a B2i Digital Featured Company, will present its clinical and commercial progress at the Emerging Growth Conference 91 on April 2, 2026, at 10:15 AM ET. The presentation will be conducted via interactive webcast, and investors, advisors, and analysts are invited to attend. See Jupiter Neurosciences’ B2i Digital Featured Companies profile: https://b2idigital.com/jupiter-neurosciences-1 The Emerging Growth Conference provides public companies an efficient platform to communicate new developments to the investment community, with an audience that includes potentially tens of thousands of individual and institutional investors as well as advisors and analysts. The company is expected to highlight its clinical and commercial progress, including the Phase IIa clinical program in Parkinson’s disease, the broader CNS and rare disease pipeline, and the Nugevia™ consumer longevity product line, all powered by the company’s proprietary JOTROL™ platform. Register for the live webcast: https://goto.webcasts.com/starthere.jsp?ei=1748971&tp_key=add80b0ab6&sti=juns An archived webcast will be available after the event on EmergingGrowth.com and the Emerging Growth YouTube Channel at https://www.YouTube.com/EmergingGrowthConference. Read the full press release: https://jupiterneurosciences.com/press-releases/?i=163719 Jupiter Neurosciences is led by Christer Rosén, Founder, Chairman and CEO; Alison Silva, President and CBO; Saleem Elmasri, CPA, CFO; and Marsh Hayward, Ph.D., Co-Founder and CSO. To learn more about the company, visit www.jupiterneurosciences.com. For investor inquiries, contact [email protected]. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. $INMB, $ANVS, $AVXL, $ATHA, $XBI

$ANVS I am a shareholder and strongly favor the prospect of buntanetap successfully treating neurodegenerative diseases. Three (or four) points regarding the article: 1-highly evidence based 2-opinion article 3-written by Annovis Bio 4-paid advertisement? Remains very well written and informative.

$ANVS well written interesting article.

$ANVS This triggers multiple flags: Flag 3 — interim hype replacing endpoints ✔ Yes Flag 2 — selective storytelling ✔ Yes Flag 1 — vague magnitude language ✔ Yes

$ANVS 70%

$ANVS PATIENCE IS A VIRTUE, WON'T BE LONG NOW!!! Buntanetap is currently in a pivotal Phase 3 clinical trial for early stage of Alzheimer’s disease and is also being tested for Parkinson’s disease, both aimed at collecting sufficient data to help bring the drug to market. The Efik people who used Calabar beans were concerned with a verdict between guilt and innocence. The modern trials of the poison’s descendant will deliver a verdict of their own: between a disease that has gone unpunished for generations and the patients who have waited long enough for justice.

$ANVS Note, the article is in the Opinion section

$ANVS Link to article referenced https://www.the-scientist.com/buntanetap-from-execution-poison-to-potential-alzheimer-s-disease-drug-74274